

Supplemental Table 1 Clinical and endocrine characteristics of the 5 female patients from the pilot study in comparison to the 12 female patients of the study

	Females from pilot study	Females
N	5	12
Duration of gestation; w	39.0 ± 2.6	38.0 ± 2.6
Weight at birth; SDS	-0.45 ± 1.00	0.12 ± 0.01
Length at birth; SDS	0.28 ± 1.63	0.33 ± 1.12
Familial target height; SDS	-0.46 ± 0.94	-0.41 ± 0.80
Age at diagnosis; y	5.3 ± 2.4	4.9 ± 2.6
Bone age at diagnosis; y	3.5 ± 2.6	3.5 ± 2.3
Height at diagnosis; SDS	-3.05 ± 1.94	-3.44 ± 0.60
GH maximum at diagnosis; ng/ml	4.7 ± 1.8	5.0 ± 2.4
IGF-1 at diagnosis; SDS	-5.00 ± 2.68	-4.42 ± 2.32
Age at stop of rhGH; y	15.1 ± 2.68	15.0 ± 0.8
Duration of treatment with rhGH; y	9.8 ± 2.0	8.9 ± 2.1
Height at stop of rhGH; SDS	-0.42 ± 0.95	-0.44 ± 1.06
BMI at stop of rhGH; SDS	-0.48 ± 0.52	-0.20 ± 0.99
Malformation of the pituitary*; n	0	2
MPHD; n	0	2
TSH deficiency; n	0	2
ACTH deficiency; n	0	1
LH/FSH deficiency; n	0	2

* ectopic neurohypophysis and split infundibulum